BioLineRx (BLRX)

Business description

BioLineRx is an Israel-based biotech company focused on the in-licensing and early development of therapeutics. It has a pipeline with five clinical and 13 preclinical candidates for a variety of indications in CNS, oncology, infectious disease, cardiovascular and autoimmune disease.

Termination of coverage

Update | Pharmaceutical & healthcare | 17/05/2017

Edison Investment Research is terminating coverage on BioLineRx (BLRX). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Edison's research is freely available. We will never ask for your credit card details and you do not need to register. By downloading this research you are agreeing to our terms and conditions, which you can read in full here.

Company news

BioLineRx

Mon, 22 May 2017 10:52:30 GMT

BioLineRx

Tue, 23 May 2017 22:07:30 GMT

BioLineRx

Thu, 23 Mar 2017 11:08:32 GMT

BioLineRx

Tue, 16 May 2017 11:03:45 GMT

BioLineRx

Thu, 23 Mar 2017 11:03:45 GMT